144 related articles for article (PubMed ID: 30645056)
1. Holo-Lactoferrin Modified Liposome for Relieving Tumor Hypoxia and Enhancing Radiochemotherapy of Cancer.
Zhang Z; Yang J; Min Q; Ling C; Maiti D; Xu J; Qin L; Yang K
Small; 2019 Feb; 15(6):e1803703. PubMed ID: 30645056
[TBL] [Abstract][Full Text] [Related]
2. Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma.
Wei M; Guo X; Tu L; Zou Q; Li Q; Tang C; Chen B; Xu Y; Wu C
Int J Nanomedicine; 2015; 10():5123-37. PubMed ID: 26316745
[TBL] [Abstract][Full Text] [Related]
3. Holo-lactoferrin: the link between ferroptosis and radiotherapy in triple-negative breast cancer.
Zhang Z; Lu M; Chen C; Tong X; Li Y; Yang K; Lv H; Xu J; Qin L
Theranostics; 2021; 11(7):3167-3182. PubMed ID: 33537080
[No Abstract] [Full Text] [Related]
4. Lactoferrin modified doxorubicin-loaded procationic liposomes for the treatment of gliomas.
Chen H; Qin Y; Zhang Q; Jiang W; Tang L; Liu J; He Q
Eur J Pharm Sci; 2011 Sep; 44(1-2):164-73. PubMed ID: 21782939
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular carcinoma targeting effect of PEGylated liposomes modified with lactoferrin.
Wei M; Xu Y; Zou Q; Tu L; Tang C; Xu T; Deng L; Wu C
Eur J Pharm Sci; 2012 Jun; 46(3):131-41. PubMed ID: 22369856
[TBL] [Abstract][Full Text] [Related]
6. Development of a hypoxia-triggered and hypoxic radiosensitized liposome as a doxorubicin carrier to promote synergetic chemo-/radio-therapy for glioma.
Liu H; Xie Y; Zhang Y; Cai Y; Li B; Mao H; Liu Y; Lu J; Zhang L; Yu R
Biomaterials; 2017 Mar; 121():130-143. PubMed ID: 28088075
[TBL] [Abstract][Full Text] [Related]
7. Hypoxic tumor therapy by hemoglobin-mediated drug delivery and reversal of hypoxia-induced chemoresistance.
Yang J; Li W; Luo L; Jiang M; Zhu C; Qin B; Yin H; Yuan X; Yin X; Zhang J; Luo Z; Du Y; You J
Biomaterials; 2018 Nov; 182():145-156. PubMed ID: 30121013
[TBL] [Abstract][Full Text] [Related]
8. A novel lactoferrin-modified stealth liposome for hepatoma-delivery of triiodothyronine.
Pireddu R; Pibiri M; Valenti D; Sinico C; Fadda AM; Simbula G; Lai F
Int J Pharm; 2018 Feb; 537(1-2):257-267. PubMed ID: 29294323
[TBL] [Abstract][Full Text] [Related]
9. Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery.
Chen H; Tang L; Qin Y; Yin Y; Tang J; Tang W; Sun X; Zhang Z; Liu J; He Q
Eur J Pharm Sci; 2010 May; 40(2):94-102. PubMed ID: 20298779
[TBL] [Abstract][Full Text] [Related]
10. Lactoferrin-conjugated biodegradable polymersome holding doxorubicin and tetrandrine for chemotherapy of glioma rats.
Pang Z; Feng L; Hua R; Chen J; Gao H; Pan S; Jiang X; Zhang P
Mol Pharm; 2010 Dec; 7(6):1995-2005. PubMed ID: 20957995
[TBL] [Abstract][Full Text] [Related]
11. Catalase-loaded cisplatin-prodrug-constructed liposomes to overcome tumor hypoxia for enhanced chemo-radiotherapy of cancer.
Zhang R; Song X; Liang C; Yi X; Song G; Chao Y; Yang Y; Yang K; Feng L; Liu Z
Biomaterials; 2017 Sep; 138():13-21. PubMed ID: 28550753
[TBL] [Abstract][Full Text] [Related]
12. A pH-sensitive hyaluronic acid prodrug modified with lactoferrin for glioma dual-targeted treatment.
Yin Y; Fu C; Li M; Li X; Wang M; He L; Zhang LM; Peng Y
Mater Sci Eng C Mater Biol Appl; 2016 Oct; 67():159-169. PubMed ID: 27287110
[TBL] [Abstract][Full Text] [Related]
13. Extremely Effective Chemoradiotherapy by Inducing Immunogenic Cell Death and Radio-Triggered Drug Release under Hypoxia Alleviation.
Zhu C; Guo X; Luo L; Wu Z; Luo Z; Jiang M; Zhang J; Qin B; Shi Y; Lou Y; Qiu Y; You J
ACS Appl Mater Interfaces; 2019 Dec; 11(50):46536-46547. PubMed ID: 31751119
[TBL] [Abstract][Full Text] [Related]
14. Design of Tumor Microenvironment-Responsive Drug-Drug Micelle for Cancer Radiochemotherapy.
Mao H; Xie Y; Ju H; Mao H; Zhao L; Wang Z; Hua L; Zhao C; Li Y; Yu R; Liu H
ACS Appl Mater Interfaces; 2018 Oct; 10(40):33923-33935. PubMed ID: 30205681
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin-loaded nanocarriers: A comparative study of liposome and nanostructured lipid carrier as alternatives for cancer therapy.
Fernandes RS; Silva JO; Monteiro LOF; Leite EA; Cassali GD; Rubello D; Cardoso VN; Ferreira LAM; Oliveira MC; de Barros ALB
Biomed Pharmacother; 2016 Dec; 84():252-257. PubMed ID: 27664949
[TBL] [Abstract][Full Text] [Related]
16. Derma roller® microneedles-mediated transdermal delivery of doxorubicin and celecoxib co-loaded liposomes for enhancing the anticancer effect.
Ahmed KS; Shan X; Mao J; Qiu L; Chen J
Mater Sci Eng C Mater Biol Appl; 2019 Jun; 99():1448-1458. PubMed ID: 30889679
[TBL] [Abstract][Full Text] [Related]
17. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
Li X; Ding L; Xu Y; Wang Y; Ping Q
Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
[TBL] [Abstract][Full Text] [Related]
18. A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy.
Paliwal SR; Paliwal R; Mishra N; Mehta A; Vyas SP
Curr Cancer Drug Targets; 2010 May; 10(3):343-53. PubMed ID: 20370682
[TBL] [Abstract][Full Text] [Related]
19. Endocytosis and degradation of bovine apo- and holo-lactoferrin by isolated rat hepatocytes are mediated by recycling calcium-dependent binding sites.
McAbee DD; Nowatzke W; Oehler C; Sitaram M; Sbaschnig E; Opferman JT; Carr J; Esbensen K
Biochemistry; 1993 Dec; 32(49):13749-60. PubMed ID: 8257710
[TBL] [Abstract][Full Text] [Related]
20. Octreotide-modification enhances the delivery and targeting of doxorubicin-loaded liposomes to somatostatin receptors expressing tumor in vitro and in vivo.
Sun M; Wang Y; Shen J; Xiao Y; Su Z; Ping Q
Nanotechnology; 2010 Nov; 21(47):475101. PubMed ID: 21030757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
